Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

A daily pill for obesity? zenagamtide faces its biggest test yet.

NCT ID NCT07720271

Disease control Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 22, 2026 · Last updated Aug 26, 2026 · Updated 4 times

Summary

This phase 3 trial is testing whether an experimental once-daily oral drug called zenagamtide can safely help people with excess body weight lose weight. Around 950 adults aged 18 and older with overweight or obesity will be randomly assigned to receive either zenagamtide or a placebo tablet each day. The main question is how much body weight changes over the study period, with secondary measures including waist circumference and blood pressure.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
an experimental once-daily oral drug called zenagamtide
What this could lead to
If it works, this could offer a convenient daily pill for weight loss, potentially helping many people manage obesity.
What could go wrong
This is a phase 3 trial, but the drug is still experimental. It may not prove more effective than placebo, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 950 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Aug 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female (sex at birth). * Age 18 and older (both inclusive) at time of signing the informed consent. Exclusion Criteria: * Glycated haemoglobin (HbA1c) more than or equal to (≥) 6.5% \[48 millimoles per mole (mmol/mol)\] as measured by the central laboratory at screening. * History of type 1 or type 2 diabetes mellitus as declared by the participant or reported in the medical records. * Treatment with glucagon-like peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1/gastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment) or amylin analogues before screening.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity Overweight

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    37 sites. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Amarillo Medical Specialists

    Amarillo, Texas, 79124, United States

  • Chambliss Clinical Trials LLC

    Montgomery, Alabama, 36106, United States

  • Clinical Investigation Spec Gurnee

    Gurnee, Illinois, 60031, United States

  • Clinical Neuroscience Solution

    Orlando, Florida, 32801, United States

  • Clinical Res Collaborative

    Cumberland, Rhode Island, 02864, United States

  • Coastal Carolina Research Ctr

    North Charleston, South Carolina, 29405, United States

  • Comprehensive Weight Ctrl Prog

    New York, New York, 10021, United States

  • Diablo Clinical Research, Inc.

    Walnut Creek, California, 94598, United States

  • ERG Holding Company, LLC / Evolution Research Group, LLC

    Delray Beach, Florida, 33445, United States

  • East West Medical Research Institute_Honolulu

    Honolulu, Hawaii, 96814, United States

  • Endeavor Health

    Skokie, Illinois, 60077, United States

  • Evanston Premier Hlthcr Res

    Skokie, Illinois, 60077, United States

  • Florida Institute for Clinical Research, LLC

    Orlando, Florida, 32825, United States

  • Great Lakes Clinical Trials

    Chicago, Illinois, 60640, United States

  • Health Res of Hampton Roads

    Newport News, Virginia, 23606, United States

  • Hillcrest Clinical Research

    Simpsonville, South Carolina, 29681-1538, United States

  • Hope Clin Res & Wellness

    Conyers, Georgia, 30094, United States

  • Jacksonville Ctr Clin Res

    Jacksonville, Florida, 32216, United States

  • Lynn Institute of Norman

    Norman, Oklahoma, 73072, United States

  • Medical Uni of SC Charleston

    Charleston, South Carolina, 29425, United States

  • Midwest Inst For Clin Res

    Indianapolis, Indiana, 46260, United States

  • Miguel Rebollar PA

    Hialeah, Florida, 33012, United States

  • National Clin Res Inc.

    Richmond, Virginia, 23294, United States

  • North Texas Endocrine Center

    Dallas, Texas, 75231, United States

  • Northeast Research Institute

    Fleming Island, Florida, 32003, United States

  • Northern Pines Hlth Ctr, PC

    Buckley, Michigan, 49620, United States

  • Oviedo Medical Research, LLC

    Oviedo, Florida, 32765, United States

  • Palm Research Center Inc.

    Las Vegas, Nevada, 89128, United States

  • Pinnacle Research Group LLC

    Anniston, Alabama, 36207, United States

  • Providence Medical Foundation

    Fullerton, California, 92835, United States

  • South Broward Research LLC

    Miramar, Florida, 33027, United States

  • Spartanburg Medical Research

    Spartanburg, South Carolina, 29303, United States

  • StudyMetrix Research LLC

    City of Saint Peters, Missouri, 63303, United States

  • Torrance Clinical Research Institute, Inc.

    Lomita, California, 90717, United States

  • Univ of Alabama Birmingham

    Birmingham, Alabama, 35294, United States

  • Univ of Colorado at Denver

    Aurora, Colorado, 80045, United States

  • Washington Cntr Weight Mgmt

    Arlington, Virginia, 22206, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.